Search

Displaying results 5421 - 5430 of 9702 in total
  1. Drug

    L-lysyl-l-arginine

    go.drugbank.com/drugs/DB19436
    Investigational

    L-lysyl-l-arginine is under investigation in clinical trial NCT03972488 (Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET).

    Synonyms: L-lysyl-l-arginine, L-arginine, l-lysyl-
  2. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. … PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  3. Drug

    Samidorphan

    go.drugbank.com/drugs/DB12543
    ApprovedInvestigational

    , and a longer half-life, making it an attractive candidate for oral dosing. … [A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability

    Salts: Samidorphan L-malate
  4. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub … >A</sub>R and 0.8 nM for AT<sub>1</sub>R).

    Categories: Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA)
  5. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    to 3690 µmol/L [A33286]. … The presence of a PEG moiety in pegvaliase-pqpz allows a reduced immune response and improved pharmacodynamic stability [A33284].

  6. Drug

    Reproterol

    go.drugbank.com/drugs/DB12846
    Investigational

    Reproterol has been used in trials studying the treatment of Asthma, Exercise-Induced.

  7. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    maintenance monotherapy resulted in a 22% reduction in the risk of death. … [A260641] Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although with a 10-fold lower affinity compared to wild-type FLT3.

  8. Drug

    Biapenem

    go.drugbank.com/drugs/DB13028
    Investigational

    It is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008]

  9. Drug

    Macimorelin

    go.drugbank.com/drugs/DB13074
    Approved

    Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). … In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability [A31481].

  10. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    Zidebactam is a diazabicyclooctane that acts both as a beta-lactamase inhibitor and as an antibacterial in its own right, selectively binding penicillin-binding protein 2. … [L63350,L63932] The combination is aimed at multidrug-resistant Gram-negative infections, a group for which treatment options are limited and where resistance to carbapenems has narrowed the available